Janssen re­ports de­cline in 2022 net prices as out-of-pock­et costs grow

While net prices for Janssen’s com­mer­cial drugs have de­clined for the sixth con­sec­u­tive year, out-of-pock­et costs have con­tin­ued to rise for some pa­tients, ac­cord­ing to the com­pa­ny’s lat­est US Pric­ing Trans­paren­cy Re­port.

The com­pa­ny pro­vid­ed $39 bil­lion last year in the form of re­bates, dis­counts and fees to com­mer­cial health in­sur­ers, phar­ma­cy ben­e­fit man­agers and oth­er in­ter­me­di­aries, it said in the re­port — a more than $5 bil­lion in­crease com­pared to 2021. A ma­jor­i­ty of that, or $11.2 bil­lion, went to com­mer­cial pay­ers and PBMs, while 16% (or $6.2 bil­lion) went to the 340B pro­gram, 13% ($5.1 bil­lion) went to Medicare and 10% ($3.8 bil­lion) to Med­ic­aid.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN